Immunotherapy
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
Immunotherapy drugs are being approved for the treatment of more and more cancers and are making significant improvements in the lives of many patients. As a result, it has become vital that the oncology team, and navigators in particular, educate themselves and their patients on the mechanisms and side effects of these drugs.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
According to preliminary data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, when used in combination with either ipilimumab or pembrolizumab, talimogene laherparepvec (T-VEC) demonstrated promising efficacy with minimal added toxicity.
November 2016 Vol 7, No 10 | November 2, 2016
Recent approvals of several checkpoint inhibitors across multiple cancer settings have brought more than just new and improved treatments to the clinic.
November 2016 Vol 7, No 10 | November 2, 2016
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented at the European Society for Medical Oncology 2016 Congress.
August 2016 Vol 7, No 7 | August 3, 2016
Immunotherapy is changing the landscape of therapy for patients with cancer and is resulting in a new population of cancer survivors for whom survivorship issues will need to be evaluated and addressed.
June 2016 Vol 7, No 5 | June 7, 2016
Response is a poor outcome measure of immunotherapy, according to Tanguy Seiwert, MD, who addressed this and other concerning issues in immunotherapy at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
June 2016 Vol 7, No 5 | June 7, 2016
The revised guideline (Version 2.2016) for the management of advanced melanoma, released by the National Comprehensive Cancer Network (NCCN), shows increasing appreciation for the use of immune checkpoint inhibitors and targeted agents, as more data establish these drug classes as having superior efficacy to traditional chemotherapy.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512